How we verify prices
Most sites quote GLP-1 prices without saying where the number came from. Here is exactly how we handle them.
One record per price
We save each price as one record with these details: the medicine, the form (such as a pen, vial or tablet), the strength, where you buy it, the amount, the period it covers, the conditions attached, the source page and an exact quote from that page.
Every price table and every calculator reads from those same records, so a number can’t differ from one page to another.
Primary sources only
A primary source is the original page, not someone else’s summary of it. We read prices on the manufacturer’s own pages (Lilly, LillyDirect, Novo Nordisk, NovoCare), on government pages (TrumpRx.gov, Medicare.gov, CMS.gov) and on each telehealth provider’s own pricing page. We never take a price from a news article, a review site or a forum.
The source sits beside the number
Wherever a price appears, the link to the page we read it on appears with it. Prices can change, so confirm the amount with the program or provider before you pay.
The programs we cover
The rules below are summarized from each program’s own page. Click through for the full terms.
Lilly list price (WAC)
The list price is the wholesale acquisition cost (WAC), the price at which Lilly sells to wholesalers. Almost nobody pays it directly: what you pay depends on your insurance, pharmacy charges and any savings program. Lilly quotes it per fill or per month (28 days for Zepbound and Mounjaro, four pens; 30 days for Foundayo) and refreshes the figure from AnalySource a few times a year. For Zepbound, Lilly currently states a range ($499 to $1,086.37 per fill) rather than one figure per presentation.
“List price, also referred to as wholesale acquisition cost or WAC, is the price at which Lilly sells its products to wholesalers. The prices patients pay at the pharmacy may be different and largely depend on the out-of-pocket costs set by their insurance provider, pharmacy charges, and/or discounts or financial assistance that may be available to the patient.”
Lilly savings cards
Lilly's savings cards are for people with commercial (private or employer) drug insurance; anyone on Medicare, Medicaid, TRICARE, VA or another government program is excluded. If your plan covers the drug you pay as little as $25 per fill (1-, 2- or 3-month fills), with a cap on how much Lilly contributes per month and per year (Zepbound pen $100/month and $1,300/year; Mounjaro $150/month and $1,950/year; Foundayo $100/month and $1,000/year). If your commercial plan does not cover the drug, a separate offer sets a fixed price per month ($499 for the Zepbound single-dose pen and Mounjaro; $299 to $449 by dose for the Zepbound KwikPen; $149 to $299 by dose for Foundayo). A self-pay card gives cash patients the same KwikPen and Foundayo prices at pharmacies outside LillyDirect. Cards require activation, cannot be combined with other offers, and expire on 12/31/2026.
“You must have commercial drug insurance that covers Zepbound single-dose pen and a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $25 for a 1-month, 2-month, or 3-month prescription fill of Zepbound single-dose pen. [...] You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program [...] Card expires and savings end on 12/31/2026.”
LillyDirect self-pay
LillyDirect is Lilly's direct-to-patient pharmacy; your doctor sends the prescription to LillyDirect Pharmacy and a partner pharmacy fills it with free delivery or retail pickup. Self-pay prices are for cash-paying patients who do not use insurance and cannot claim reimbursement. Zepbound vials are sold only through LillyDirect self-pay; KwikPen, Mounjaro, Trulicity and Foundayo are also available self-pay. Higher Zepbound doses (7.5 mg and up) and Foundayo 14.5/17.2 mg use the Journey Program: you get the lower price on your first fill and on every refill bought within 45 days of receiving the previous fill; miss that window and the regular price applies (Zepbound: $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg; Foundayo: $349 for 14.5 and 17.2 mg). A month is 28 days (4 vials or 1 KwikPen) for Zepbound and 30 days for Foundayo; needles are sold separately; Lilly can change or end the offers at any time.
“†For 7.5 mg, 10 mg, 12.5 mg and 15 mg doses, prices reflect monthly cost with Zepbound Journey Program. Regular prices will apply if prescription is not refilled within 45 days ($499 for 7.5mg, $699 for 10mg, $699 for 12.5mg, and $699 for 15mg). [...] *Self-pay only. Eligibility required, terms and conditions apply. Savings subject to monthly and annual limits. Month is defined as 28-days and 4 single-dose vials.”
Medicare GLP-1 Bridge
A temporary CMS demonstration running July 1, 2026 through December 31, 2027 for people 18 or older with Medicare Part D drug coverage who start a GLP-1 for weight management and meet the BMI criteria (BMI 35+; BMI 30+ with diastolic heart failure, uncontrolled high blood pressure or CKD stage 3a+; or BMI 27+ with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease). People already getting a GLP-1 through Part D, or using it for type 2 diabetes, sleep apnea or fatty liver disease, are not eligible. Covered drugs: Foundayo tablets, Wegovy pen and pill, and the Zepbound KwikPen only (not single-dose vials or pens). Your doctor completes a prior authorization once; it stays valid for refills and dose changes through December 31, 2027. You pay a $50 copay per one-month supply (28 or 30 days) to the pharmacy; it is billed outside Part D, so it does not count toward your deductible or out-of-pocket limit and Extra Help does not reduce it.
“The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. [...] Eligible beneficiaries will have a $50 copay. Eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge are provided outside of the Part D benefit payment flow and coverage. This means that the Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary's TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries.”
Novo Nordisk list price
Novo Nordisk publishes list prices on NovoCare. The list price is the price set before any discounts or rebates; most insured people pay far less. Wegovy pen, Wegovy HD pen and Wegovy pill are each $1,349.02 per package (a box of 4 pens or a bottle of 30 tablets); Ozempic is $1,027.51 per pen; Saxenda is $1,349.02. Novo Nordisk has announced a new $675 per month list price for Wegovy, Ozempic and Rybelsus effective January 1, 2027, and says Rybelsus is being replaced by the Ozempic pill and Saxenda will be discontinued after January 2027.
“List price is the original price set for a medication by a manufacturer before any discounts or rebates are applied. However, most people don't pay list price if their health insurance covers their medications. Your out-of-pocket cost depends on your insurance coverage. Wegovy® pill has a list price of $1,349.02/package. Wegovy® pen has a list price of $1,349.02/package. Wegovy® HD pen has a list price of $1,349.02/package.”
Novo Nordisk savings offers
The Wegovy, Ozempic and Rybelsus savings offers are for people with commercial insurance that covers the drug; government beneficiaries are excluded. You pay as little as $25 per month, and Novo Nordisk covers at most $100 per 1-month fill ($200 for 2 months, $300 for 3 months). The Ozempic offer can be used for up to 48 months. The Saxenda savings offer closed to new enrollees on June 30, 2023. Offers cannot be combined with other discounts and Novo Nordisk can modify or cancel them at any time.
“*Pay as little as $25, subject to a maximum savings of $100/month. Government beneficiaries excluded. Month defined as 1 box of 4 pens of Wegovy® and 1 bottle of 30 tablets of Wegovy®. Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time.”
NovoCare Pharmacy self-pay
NovoCare Pharmacy (dispensed by CoAssist Pharmacy) ships Wegovy and Ozempic to self-paying patients, and the same self-pay offer can be used for pickup at a retail pharmacy. No insurance is used and you cannot seek reimbursement. Wegovy pill: $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) per bottle of 30. Wegovy pen: patients new to the offer pay $199 a month for up to two monthly fills of 0.25 mg or 0.5 mg through December 31, 2026, then $349 a month for 0.25 to 2.4 mg and $399 for the 7.2 mg HD pen. Ozempic pen: new patients pay $199 for the first two fills of 0.25/0.5 mg, then $349 for 0.25, 0.5 or 1 mg and $499 for 2 mg. A month is one box of pens or one bottle of tablets; Novo Nordisk can modify or cancel the offers at any time.
“bPatients new to the Wegovy® Savings Offer and NovoCare® Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg. Offer is for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg and $399 per month for Wegovy® HD (semaglutide) injection 7.2 mg. One month is defined as 1 box of 4 pens of Wegovy®. Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time.”
TrumpRx
TrumpRx.gov is a federal price-listing site; you cannot buy drugs from it. It shows out-of-pocket (self-pay) prices for patients who do not use insurance, and you agree not to seek reimbursement or count the cost toward a deductible. For Wegovy and Ozempic it issues a coupon (BIN/PCN/group) to present at a retail pharmacy; for Zepbound vials and Foundayo it sends you to LillyDirect. The prices mirror the manufacturers' own self-pay programs, including the Wegovy and Ozempic $199 new-patient offer for the first two monthly fills of the two lowest doses (through 12/31/2026) and Lilly's 45-day refill window for higher doses. Zepbound is listed as the vial only. TrumpRx prices are not creditable coverage for Medicare.
“This is an out-of-pocket price. If you have insurance, check your co-pay first—it may be even lower. [...] By continuing and using this offer, you agree that this offer is for self-pay patients only [...] you must (1) not ask your insurance to pay you back for the money that you self-paid for your medication using this offer; (2) cannot attempt to count the cost of this medicine toward your insurance deductible or out-of-pocket limit”